Regeneron Pharmaceuticals, Inc. (REGN)
$
654.04
+1.13 (0.17%)
Key metrics
Financial statements
Free cash flow per share
40.0918
Market cap
67.6 Billion
Price to sales ratio
4.7411
Debt to equity
0.0874
Current ratio
4.0633
Income quality
1.1077
Average inventory
3.2 Billion
ROE
0.1531
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Regeneron Pharmaceuticals, Inc. is engaged in the discovery, invention, development, manufacturing, and commercialization of medicines for a range of diseases globally. The operating income ratio is 0.28 indicating the company's operational profitability margin. Its diverse product range includes EYLEA, which is used to treat conditions such as wet age-related macular degeneration and diabetic macular edema, alongside treatments for myopic choroidal neovascularization and various forms of diabetic retinopathy. The company also develops and markets Dupixent for atopic dermatitis and asthma in both adults and children, Libtayo for specific cancers, and Praluent for managing familial hypercholesterolemia and cardiovascular disease. Moreover, REGEN-COV is available for treating COVID-19, while Kevzara addresses rheumatoid arthritis in adults. Regeneron has also made strides in treating Zaire ebolavirus infections through Inmazeb and offers ARCALYST for various periodic syndromes, including familial cold auto-inflammatory syndrome. Furthermore, ZALTRAP is indicated for metastatic colorectal cancer, as the company continually innovates therapies for eye, allergic, inflammatory, cardiovascular, metabolic, infectious, and rare diseases, as well as cancer, pain, and hematologic conditions. The net income ratio stands at 0.31 reflecting the company's profitability margin, while the reported income before tax is 4,779,900,000.00 showcasing its pre-tax profitability. Additionally, the earnings per share (EPS) is reported at $40.90 indicating the company's profitability on a per-share basis. The company earned an interest income of $711,400,000.00 showcasing its financial investments. With a large market capitalization of $67,550,767,265.00 Regeneron is a dominant player in the biopharmaceutical industry, contributing significantly to the overall market landscape. The stock is priced at $591.99 positioning it in the higher-end market, and it has an average trading volume of 1,073,507.00 indicating moderate liquidity. As a key player in the Biotechnology industry, Regeneron drives innovation and growth, establishing its presence in the Healthcare sector. The company's collaborative efforts through various agreements with notable partners and institutions further reinforce its strategic positioning and commitment to advancing healthcare solutions.
Is Regeneron Pharmaceuticals, Inc. (REGN) a good investment?
Investing in Regeneron Pharmaceuticals, Inc. (REGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A, with a Bullish outlook. Always conduct your own research before investing.
What is Regeneron Pharmaceuticals, Inc. (REGN)'s stock forecast?
Analysts predict Regeneron Pharmaceuticals, Inc. stock to fluctuate between $476.49 (low) and $862 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Regeneron Pharmaceuticals, Inc.'s market capitalization?
As of 2025-10-30, Regeneron Pharmaceuticals, Inc.'s market cap is $67,550,767,265, based on 103,282,318 outstanding shares.
How does Regeneron Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Regeneron Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Regeneron Pharmaceuticals, Inc. pay dividends?
Regeneron Pharmaceuticals, Inc. pays dividends. The current dividend yield is 0.54%, with a payout of $0.88 per share.
How can I buy Regeneron Pharmaceuticals, Inc. (REGN) stock?
To buy Regeneron Pharmaceuticals, Inc. (REGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for REGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Regeneron Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Regeneron Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $14,202,000,000 | EPS: $40.90 | Growth: 10.39%.
Where can I find Regeneron Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.regeneron.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Regeneron Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Regeneron Pharmaceuticals, Inc. stock?
All-time high: $1,211.20 (2024-08-27) | All-time low: $476.49 (2025-06-05).
What are the key trends affecting Regeneron Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions
seekingalpha.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman Marion McCourt - Executive Vice President of Commercial Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Tyler Van Buren - TD Cowen, Research Division Evan Seigerman - BMO Capital Markets Equity Research Brian Abrahams - RBC Capital Markets, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Alexandria Hammond - Wolfe Research, LLC Christopher Schott - JPMorgan Chase & Co, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Presentation Operator Welcome to the Regeneron Pharmaceuticals Third Quarter 2025 Earnings Conference Call. My name is Shannon, and I will be your operator for today's call.
zacks.com
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Regeneron (REGN) came out with quarterly earnings of $11.83 per share, beating the Zacks Consensus Estimate of $9.44 per share. This compares to earnings of $12.46 per share a year ago.
reuters.com
Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending its shares up 5.6% premarket.
globenewswire.com
TARRYTOWN, N.Y., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2025 and provided a business update.
forbes.com
Here is why we believe Regeneron Pharmaceuticals (REGN) stock is worthy of consideration as a value investment. It is presently trading nearly 38% lower than its one-year peak, and is also being traded at a price to sales multiple that is beneath the average for the past three years.
zacks.com
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
zacks.com
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
zacks.com
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
See all news
